Figure 4From: Safety and effectiveness of adalimumab in patients with rheumatoid arthritis over 5 years of therapy in a phase 3b and subsequent postmarketing observational studyMean change of Health Assessment Questionnaire Disability Index (HAQ DI) from baseline in patients (A) with sustained low disease activity (LDA) defined as Simplified Disease Activity Index (SDAI) ≤ 11 for at least 6 months and without sustained LDA and (B) with sustained remission (REM) defined as SDAI ≤ 3.3 for at least 6 months and without sustained REM. Data are shown as observed values for all evaluable patients at each time point during long-term treatment with adalimumab (ADA). *Denotes significance from baseline, P ≤0.001. LO, last observation.Back to article page